The PrEP Journey

Program Description 

HIV prevention with preexposure prophylaxis (PrEP) is an essential tool for clinicians to help end the HIV epidemic. In this case-based interactive activity, you will learn the basics of assessing HIV risk, conversing with patients about sexual health, and providing PrEP, from initiation to monitoring and follow-up. Then, more challenging cases will illustrate the nuances of providing PrEP based on patient characteristics and preferences. Prof Daniel Richardson and nurse practitioner Shauna Applin will review clinical evidence and discuss strategies to address the different challenges involved in providing oral and long-acting injectable PrEP, placed in the context of case-based mile markers along the PrEP Journey.

Target Audience 

This activity addresses identified knowledge and practice gaps related to HIV prevention among primary care physicians (PCPs), nurse practitioners (NPs), and physician assistants (PAs), as well as obstetrics/gynecology (OB/GYN) and pediatric specialists based both within and outside of the United States.

Educational Objectives

Upon completion of this activity, participants should be able to: 

• Describe the risk of HIV acquisition based on demographic, geographic, and behavioral factors 
• Discuss the clinical eligibility and laboratory requirements for various HIV-prevention options  
• Identify appropriate HIV-prevention regimens to individualize care, increase adherence, and address potential health equity concerns  
• Address factors that emerge from patient monitoring and ongoing management, including treatment resistance and stopping or switching PrEP regimens

Faculty and Disclosure of Conflicts of Interest 

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company. 

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity: 

Shauna Applin, A-NP, AAHIVS, CNM: Consulting Fees: Gilead, Merck, Janssen; Contracted Research: Gilead (PI); Speakers Bureau: Gilead, Merck

Daniel Richardson, FRCP, FAChSHM: Nothing to disclose

The PACE planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Integritas Communications.  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education 

PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Nursing Continuing Professional Development 

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hours.  

PACE Contact Information  

For additional information about the accreditation of this activity, please visit https://partnersed.com

Instructions for Credit

In order to obtain your CE credit, please follow the steps below:  

1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.  
2. Complete the Preactivity Questions.  
3. Review the activity content.  
4. Achieve a grade of 70% or higher on the Postactivity Test Questions and complete the Evaluation. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.